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Abstract
Background: Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that
has given promising preliminary results in adult myeloid CD33+ AML. We conducted a
retrospective multicenter study of 12 children treated with GO on a compassionate basis (median
age 5.5 y). Three patients (2 MDS/AML, 1 JMML) were refractory to first-line treatment, 8 patients
with de novo AML were in refractory first relapse, and one patient with de novo AML was in 2nd
relapse after stem cell transplantation (SCT). CD33 expression exceeded 20% in all cases.
Methods: GO was administered alone, at a unit dose of 3–9 mg/m2, once (3 patients), twice (3
patients), three (5 patients) or five times (1 patient). Mean follow-up was 128 days (8–585 d).
Results: There were three complete responses (25%) leading to further curative treatment (SCT).
Treatment failed in the other nine patients, and only one patient was alive at the end of follow-up.
NCI-CTC grade III/IV adverse events comprised hematological toxicity (n = 12),
hypertransaminasemia (n = 2), allergy and hyperbilirubinemia (1 case each). There was only one
major adverse event (grade IV allergy). No case of sinusoidal obstruction syndrome occurred.
Conclusion: These results warrant a prospective trial of GO in a larger population of children
with AML.
Background
Despite gradual improvements over the years, the survival
rate among children with acute myeloblastic leukemia
(AML) was only 50 to 60% during the last decade [1-6].
About 10% of children do not enter first complete remis-
sion (CR). In addition, second CR is often difficult to
achieve, even with high-dose cytarabine. Patients who
relapse therefore have few therapeutic options. New cyto-
toxic agents, including nucleoside analogs, are currently
being evaluated [2,7-9].
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An alternative to chemotherapy (CT) is to target leukemic
blasts with monoclonal antibodies. Approximately 80%
to 90% of pediatric AML patients have myeloid blast cells
that express the CD33 surface antigen [10]. This antigen is
present on normal hematopoietic progenitor cells but not
on normal hematopoietic stem cells or on non hemat-
opoietic cells [11]. Gemtuzumab ozogamicin (GO) is an
immunoconjugate consisting of a humanized anti-CD33
IgG4κ  antibody linked to the cytotoxic compound N-
acetyl-γ-calicheamicin dimethylhydrazine, a member of
the enediyne antitumor antibiotic family [12,13]. GO
selectively targets CD33+ cells and was specifically devel-
oped for the treatment of AML. After receptor binding, the
complex is rapidly internalized and calicheamicin is
released intracellularly. Calicheamicins are known for
their extreme cytotoxic potency, attributed to double-
stranded DNA cleavage at specific sequences [14,15]. In
phase I/II studies, approximately 30% of adults with
relapsed AML responded to GO [12,13,16]. Severe myelo-
suppression is common, however, and platelet recovery
can be slow, probably owing to CD33-expressing platelet
precursor damage [13]. Toxicity is relatively mild com-
pared with classical multiagent CT, especially with regard
to mucositis and infections [17], but GO can cause severe
liver toxicity in the form of a sinusoidal obstruction syn-
drome (SOS) [18,19] Several factors can increase the risk
of hepatotoxicity, including previous stem cell transplan-
tation (SCT) [20]. Prior exposure to GO is also known to
increase the risk of SOS in patients who subsequently
undergo myeloablative SCT [21] GO has been approved
in the United States for the treatment of elderly patients
with relapsed AML [16].
GO has rarely been used in children. Sievers et al reported
preliminary results of a phase I ascending-dose study of
GO in 18 children with relapsed or refractory AML [22].
Likewise, Zwaan et al used GO (up to three doses) to treat
15 children with relapsed/refractory CD33+ AML, on a
compassionate-use basis [23,24]. More recently Arceci et
al reported a dose-escalation study of 29 children with
multiple relapsed or primary refractory AML [25]. Here we
report our experience with GO monotherapy in 12 chil-
dren with relapsed or refractory AML.
Methods
This retrospective study involved 12 children treated with
GO between March 1999 and April 2004 on a compas-
sionate-use basis in four pediatric centers. GO therapy was
approved by the french agency for health product safety
(AFSSAPS), and the guardians' and/or patients' informed
consent was obtained. The cutoff date for this analysis was
30 September 2004. The children had myelodysplasia
(MDS)/AML refractory to standard induction therapy (n =
2), juvenile myelomonocytic leukemia (JMML) refractory
to several cytotoxic drugs and retinoic acid (n = 1), first
relapse of AML refractory to reinduction therapy (n = 8),
or AML in second relapse after SCT (n = 1).
Table 1: Characteristics of 12 children treated with GO.
Nr Age at 
diagnosis 
(yrs)
Gender FAB Cytogenetic Features Molecular 
Biology
WBC at diag-
nosis (.109/L)
WBC before 
GO (.109/L)
Nb of 
Relapses
Treatment 
before 
relapse or 
GO
#1 1.8 M JMML N N 25.2 1.2 R Other
#2 1.1 M AML7 N N 23.0 5.0 1 CT♣
#3 1.1 F AML7 53,XX,+X,t(1;22)(p13;q13)+5,+6,
+19,+20,+21 [18]
OTT/MAL 9.0 8.2 2 CT♣
IL2
CB-SCT
#4 14.0 F AML1 47,XX,+8 [20] N 27.7 2.2 1 CT♣
#5 14.7 M MDS/AML6 N N 1.5 0.9 R CT♣
MUD-SCT
#6 17.2 F AML2 46,XX,t(6;9)(p23;q34) [25] DEK/CAN 3.3 10.9 1 CT♣
#7 2.8 M MDS/AML7 46,XY,del(3)(q24;q26) [6] N 11.4 22.0 R CT♣
#8 2.5 M AML7 N N 4.8 7.4 1 CT♣
#9 1.0 F AML7 46,t(2;16) [20] N 20.0 4.0 1 CT♣
#1
0
8.2 M AML5 46,XY,t(6;11)(q26;q23),del(12)(p
11;p12) [17]
N3 8 . 0 0 . 2 1 C T ♣
#1
1
13.5 M AML6 47,XY,del(3)(q23;qter), +8 [9] N 2.6 1.2 1 Other
#1
2
10.0 F AML2 45,XX,-7 [23] N 26.0 2.4 1 CT♣
FAB indicates French-American-British classification; WBC, white blood cell; M, male; F, female; JMML, juvenile myelomonocytic leukemia; MDS, 
myelodysplasia; AML, acute myeloblastic leukemia; N, normal; R, refractory; CB-SCT, cord blood-stem cell transplantation; IL2, interleukine 2; 
MUD-SCT, matched unrelated donor-stem cell transplantation.
♣ CT, chemotherapy according to national contemporary protocols (LAME 91, LAME 99, ELAM 02, EORTC 58921)BMC Cancer 2006, 6:172 http://www.biomedcentral.com/1471-2407/6/172
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The patients' characteristics at initial diagnosis are shown
in Table 1. Median age was 5.5 years (1.0–17.2 y), and
there were 7 boys and 5 girls. The initial diagnoses were de
novo AML in 9 cases (M1 = 1; M2 = 2; M5 = 1, M6 = 1; M7
= 4), MDS/AML in 2 cases (M6 = 1; M7 = 1) and JMML in
1 case. FAB M6/M7 and transformed MDS were over-rep-
resented, reflecting the poor prognosis of these patients.
The median white blood cell (WBC) count at diagnosis
was 15.7 × 109/L (1.5–38.0 × 109/L). Cytogenetic analysis
showed intermediate-risk AML in 8 cases and high-risk
AML in 4 cases.
First-line CT was based on four different intensive regi-
mens consisting of repeated courses of cytarabine plus
intercalating agents. The patient with refractory JMML
(Table 2, patient #1) received a combination of 6-mercap-
topurine, etoposide, cytarabine, hydroxyurea and 6-thio-
guanine, plus 13 cis-retinoid acid, without responding.
The two patients with primary refractory MDS/AML
(patients #5 and #7) had received standard induction CT
(cytarabine 200 mg/m2/d × 7 days plus mitoxantrone 12
mg/m2/d × 5 days), without responding. They were fur-
ther treated with high-dose cytarabine and amsidine, but
again no response was obtained. One of the two patients
then received several courses of low-dose cytarabine plus
etoposide before undergoing matched unrelated donor
(MUD)-SCT while in partial remission. He relapsed 14
months later and was again refractory to low-dose cytara-
bine plus etoposide at the time of GO therapy.
The nine relapsing patients had been treated with FLAG (a
combination of fludarabine, high-dose cytarabine and
granulocyte colony-stimulating factor), [26] with or with-
out anthracyclines. Eight of these nine patients (patients
#2, #4, #6, #8, #9, #10, #11, #12) were in refractory rein-
duction CT before receiving GO. The ninth patient (UPN
#3) entered CR2 after reinduction CT and underwent
cord-blood SCT. This patient had no sign of active hepatic
graft-versus-host disease or SOS and had normal transam-
inase and bilirubin values when GO was administered for
very early post-SCT relapse.
The median interval between initial diagnosis and GO
administration was 11.5 months (4.8–45.5 months). All
patients had CD33+ myeloid leukemia at the time of GO
therapy, with a median proportion of bone marrow blasts
of 47% (20 – 98%). The median WBC count was 3.2 ×
109/L (0.2–22.0 × 109/L). GO was given to 8 patients at a
total dose of 9 mg/m2, administered in a single dose (n =
3) or divided into 3 doses given on days 1, 4 and 7 (n =
5). Patient #9 received 5 doses of 3 mg/m2 (days 1, 4, 7,
28 and 31). Patient #10 received two doses of 9 mg/m2
each (days 1 and 14). Patient #11 received two doses of
7.5 mg/m2 each (days 1 and 16). Patient #12 received one
dose of 6 mg/m2 (day 1) and another dose of 9 mg/m2
(day 16) (see Table 2). The unit doses and dosing intervals
were based on those used in adults and in the pediatric
studies of Sievers et al [22] and Zwaan et al [23], and were
decided on by the physicians in charge of each patient.
Fractionated doses were adopted secondarily, as they were
reported to be associated with less SOS in adults (Raffoux
E et al, annual meeting of the french hematologic society
SFH, 2000, abstract). This schedule was chosen in the
ongoing french MyloFrance protocol in adults.
Complete responses to GO were defined on the basis of
the following consensus criteria: a bone marrow blast pro-
portion of 5% or less, in the absence of leukemic cells in
peripheral blood or elsewhere. The definition of CR
included adequate recovery of peripheral blood cell
counts (granulocytes > 1 × 109/L and platelets > 100 ×
109/L with at least one week of transfusion independ-
ence). CRp was defined as a response with incomplete
platelet recovery but with platelet transfusion independ-
ence [12]. Adverse events are reported according to the
National Cancer Institute common toxicity criteria (NCI-
CTC; 2003 revision) [27].
Results
Responses and major toxicities are summarized in Table
2.
Responses
Median follow-up after the beginning of GO treatment
was 128 days (8–585 d). As shown in Table 2, responses
were observed in 3 (25%) of the 12 patients. One patient
entered CR on day 39, after 5 doses of 3 mg/m2, and two
patients entered CRp, on day 28 after 3 doses of 3 mg/m2
and on day 24 after 2 doses of 7.5 mg/m2. No change in
bone marrow blast count was observed in two patients on
day 15. Six patients progressed before day 15 of GO ther-
apy. Patient #10 had paucicellular bone marrow, with few
leukemic blasts, on day 66.
The three responding patients subsequently received SCT.
Patient #5 received MUD-SCT 83 days after the first GO
infusion and died on day 260 from infectious complica-
tions of SCT. Patient #9 received three GO doses of 3 mg/
m2, which reduced the proportion of bone marrow blasts
from 86% at baseline to 20% on day 28. Because GO was
well tolerated, two more doses of 3 mg/m2 GO were given,
and CR2 was achieved on day 39. The patient relapsed 6.5
months after MUD-SCT. Further GO therapy controlled
the bone marrow blast count, with no significant adverse
effects, for 12.5 months after SCT. The patient finally died
in blast crisis after a cumulative GO dose of approximately
45 mg/m2. Patient #11 received haplo-SCT 72 days after
the first GO infusion. Bone marrow relapse occurred 9.6
months after SCT and the patient died 11.2 months afterBMC Cancer 2006, 6:172 http://www.biomedcentral.com/1471-2407/6/172
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SCT. CR or CRp was maintained for 205, 260 and 288
days in the three responding patients.
Two patients (#4 and #6) who received three GO doses of
3 mg/m2 (on days 1, 4 and 7) had no change in their bone
marrow blast counts on day 15. They died of disease pro-
gression 97 and 101 days after the first GO infusion. Five
patients (#1, #2, #3, #7 and #8) who progressed less than
15 days after GO treatment initiation developed grade IV
hematologic toxicity related to the underlying leukemia.
Patient #2 died from disease progression on day 8 after
GO initiation. The remaining four patients received palli-
ative therapy and died a median of 116 days after GO ini-
tiation. Patient #10, who did not respond to GO by day 66
(paucicellular bone marrow, with a few leukemic blasts)
also developed grade IV hematologic toxicity probably
Table 2: Modality and dose of GO therapy and treatment responses in 12 children with relapsed/refractory myeloid leukemia
Nr Disease 
status
Nb of GO 
courses
GO dose/
course
BM before 
GO % *
Diag/GO 
(days)
Response GO toxicity (NCI-CTC) ¥ Further 
treatment
Follow-up
#1 De novo 
refractory
1 1 × 9 mg/m2 
(d1)
40 335 DP Anaphylaxis
Transient grade IV 
hyperbili.
Grade III transa. elevation
None V from 
JMML
#2 Refractory 
relapse
1 1 × 9 mg/m2 
(d1)
98 250 DP No None V from AML
#3 Post-SCT 
2nd relapse
1 3 × 3 mg/m2 
(d1,d4,d7)
49 555 DP Grade III febrile 
neutropenia
Grade III transa. elevation
None V from AML
#4 Refractory 
relapse
1 3 × 3 mg/m2 
(d1,d4,d7)
43 177 DP Grade II vomiting
Grade III febrile 
neutropenia
Grade II stomatitis
None V from AML
#5 De novo 
refractory
1 3 × 3 mg/m2 
(d1,d4,d7)
45 667 CRp 
(d28)
No MUD-SCT V from SCT
#6 Refractory 
relapse
1 3 × 3 mg/m2 
(d1,d4,d7)
73 579 DP Grade II stomatitis None V from AML
#7 De novo 
refractory
1 1 × 9 mg/m2 
(d1)
59 145 DP Septic shock
Grade II vomiting
Grade I fever
None V from AML
#8 Refractory 
relapse
1 3 × 3 mg/m2 
(d1,d4,d7)
96 298 DP Grade II vomiting
Grade I fever
None V from AML
#9 Refractory 
relapse
2 3 × 3 mg/m2 
(d1,d4,d7) 
and 2 × 3 
mg/m2 ‡
86 162 CR (d39) No MUD-SCT V from AML 
§
#10 Refractory 
relapse
1 2 × 9 mg/m2 
(d1,d14)
25 357 DP Grade III febrile 
neutropenia
Grade II transa elevation
Grade II 
hyperbilirubinemia
Grade III acute 
cholecystitis
Grade IV hemorragic 
cystitis
None V from AML
#11 Refractory 
relapse
1 2 × 7.5 mg/
m2 (d1,d16)
20 513 CRp 
(d24)
Grade II fever
Grade II vomiting
Haplo-SCT V from AML
#12 Refractory 
relapse
16  m g / m 2 
(d1)+9 mg/
m2 (d16)
35 1367 DP Grade II pancreatitis
Grade II fever
Grade II vomiting
Arsenic 
clofarabin.
Alive in PR 
♣
BM: bone marrow; SCT, stem cell transplantation; MUD, matched unrelated donor; CR, complete remission; CRp, complete remission without 
total platelet recovery; PR, partial remission; DP, disease progression.
*Bone marrow blast percentage. CD33 expression was greater than 20% before GO in all cases.
¥All patients experienced NCI-CTC grade III to IV hematological toxicity, which is not mentioned here.
‡This patient was treated with 3 × 3 mg/m2 of GO leading to a reduction in BM blasts from 86 to 20% at d28. Because of good tolerance, two more 
doses of 3 mg/m2 were administered and CR was obtained at d39.
§This patient relapsed 69 days after MUD-SCT but a drastic reduction of BM blasts was obtained with 5 weekly doses of 3 mg/m2 GO without any 
significant adverse effects. He received GO maintenance therapy but died 12 months after MUD-SCT.
V Death
♣ This patient was scheduled to receive MUD-SCT.BMC Cancer 2006, 6:172 http://www.biomedcentral.com/1471-2407/6/172
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related to the underlying disease. He died in blast crisis
238 days after GO initiation. Patient #12 did not respond
by day 31, after two doses of GO (day 1 = 6 mg/m2, day
16 = 9 mg/m2). He then received alternative treatments
and was alive in partial remission 120 days after GO
administration. MUD-SCT was scheduled one month
later.
Only one of the 12 patients was alive at the cutoff date for
this analysis.
Toxicity
In the three responding patients (#5, #9, #11), GO was
well tolerated, with the exception of NCI-CTC grade III-IV
hematologic toxicity. Patient #1 developed severe infu-
sion-related hypotension (NCI-CTC grade IV) and fever,
necessitating fluid support. Three other patients had
febrile reactions during GO infusion (patients #7, #8 and
#12). Five patients (#4, #7, #8, #11 and #12) had grade II
vomiting during the infusion or the subsequent 24 hours.
Two patients (#4 and #6) had grade II stomatitis, but the
cause (GO or prolonged neutropenia?) was not deter-
mined. Four patients developed secondary infections:
patient #7 had preseptic shock on day 12, but no bacterial
or fungal pathogen was identified; patient #10 developed
acute cholecystitis; and patients #3 and #4 had grade III
febrile neutropenia with no identified site of infection.
Patients #1 and #3 had transient NCI-CTC grade III
transaminase elevation, accompanied by transient grade
IV hyperbilirubinemia in one case (patient #1), but with-
out ascites or weight gain suggestive of SOS. None of the
12 patients developed SOS.
Discussion
We treated 12 children with relapsed or refractory mye-
loid leukemia with GO (3–18 mg/m2, up to 5 infusions)
on a compassionate-use basis. The prognosis of such chil-
dren is very poor: three of our patients with newly diag-
nosed JMML or MDS/AML were refractory to several
different induction regimens; the remaining nine patients
were either refractory to reinduction therapy or in second
relapse after SCT. Further use of intensive CT is limited by
its toxicity [28,29].
GO monotherapy thus yielded a response rate of 25% (3/
12 patients). This rate is similar to that obtained in adults
with relapsed AML [12,13]. However, available adult
studies only included patients in first AML relapse. As in
our series, the 15 children treated by Zwaan et al and the
29 children treated by Arceci et al with GO monotherapy
had more advanced disease and, potentially, more cumu-
lative toxicities [23,25]. Two CRp was followed by SCT in
the Zwaan et al's series, and the two children were alive
without significant GO/SCT-related toxicity, albeit with
short follow-up (6 and 9 months). Likewise, our three
patients who entered CR or CRp subsequently underwent
SCT, and no major hepatotoxicity occurred. CR or CRp
was maintained for 7 to 10 months before death or further
relapse. In the dose-escalation study reported by Arceci et
al, 4 patients experienced CR and 4 experienced CRp, for
8 (28%) overall remissions after GO therapy. Response
rates were comparable in patients with refractory (30%)
and relapsed (26%) disease. Most patients died of pro-
gressive disease (22/29), unfortunatly comprising 4/8
patients in CR or CRp after GO. These data suggest a need
for intensive therapy following GO-induced remission, as
in adults [30].
Considering the toxicity of GO, NCI-CTC grade IV hema-
tologic toxicity occurred in all 12 children of our series. In
responders, it was probably related to expression of the
CD33 target by normal bone marrow progenitors. In non
responders, it was difficult to determine the respective
roles of GO and the underlying leukemia. With regard to
non hematologic adverse events, GO was relatively well
tolerated compared to intensive CT, with no cases of
mucositis and only one noteworthy infection. This is in
keeping with previous pediatric results [23,25]. GO ther-
apy is an established risk factor for SOS [18-20]. No cases
of SOS occurred in our series, even after SCT in the three
responding patients. Zwaan et al reported only one case of
SOS among 15 GO-treated children, occurring after SCT
[23]. Arceci et al described an 24% overall incidence of
SOS [25]. SOS developed in 6 of 7 patients after they
underwent SCT. They had been exposed to GO within 3.5
to 4 months of transplantation. Two other patients who
underwent SCT more than 4 months from GO exposure
did not developed SOS. These findings are consistent with
similar adult series [21]. Taken together, these data sug-
gest that the time from treatment with GO to SCT for
refractory/relapsed AML appears to be important with
respect to the incidence of SOS after SCT. The incidence of
liver dysfunction in GO-treated children is similar to that
observed in the largest adult series [13], in which liver dys-
function was generally transient and never life-threaten-
ing.
GO was well tolerated, even during repeated infusions.
One of our patients (#9) received a cumulative dose of
approximately 45 mg/m2 over a 14-month period. One
patient in Zwaan's series was treated repeatedly with GO,
with relatively long intervals between the infusions, and
responded each time without showing signs of additional
toxicity [23]. Palliative treatment thus appears to be feasi-
ble with repeated GO infusions.
Conclusion
This report confirms that GO is clinically active in chil-
dren with relapsed/refractory CD33+ AML. Despite its
good tolerability, GO monotherapy only induces aBMC Cancer 2006, 6:172 http://www.biomedcentral.com/1471-2407/6/172
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response rate of 25 to 33%, similar to that previously
reported in adults. In a recent trial, GO was combined
with intensive CT as first-line treatment for AML in 72
patients aged 17 from 59 years [31]. Certain schedules of
CT-GO combination induction therapy yielded CR in
91% of patients, 78% of whom were in continuous CR at
8 months. GO should be tested prospectively in a larger
population of children with AML, with more stringent eli-
gibility criteria and treatment schedules, in association
with CT.
Competing interests
The autor(s) declare that they have no competing inter-
ests.
Authors' contributions
Conception and design: BB, AB, GL; analysis and interpre-
tation of data: BB, AA, CG, KY, TL, YB, GL, AB; drafting the
article or revising it critically for important intellectual
content: AB, GL, BB, AA; final approval of the version to
be published: all authors.
References
1. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E,
Masera G, Rondelli R, Zanesco L, Mandelli F: Prospective compar-
ative study of bone marrow transplantation and postremis-
sion chemotherapy for childhood acute myelogenous
leukemia. The Associazione Italiana Ematologia ed Oncolo-
gia Pediatrica Cooperative Group.  J Clin Oncol 1993,
11:1046-54.
2. Behar C, Suciu S, Benoit Y, Robert A, Vilmer E, Boutard P, Bertrand
Y, Lutz P, Ferster A, Tokaji E, Manel AM, Solbu G, Otten J: Mitox-
antrone-containing regimen for treatment of childhood
acute leukemia (AML) and analysis of prognostic factors:
results of the EORTC Children Leukemia Cooperative Study
58872.  Med Pediatr Oncol 1996, 26:173-9.
3. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S,
Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur
DC, Lange BJ: Timed-sequential induction therapy improves
postremission outcome in acute myeloid leukemia: a report
from the Children's Cancer Group.  Blood 1996, 87:4979-89.
4. Stevens RF, Hann IM, Wheatley K, Gray RG: Marked improve-
ments in outcome with chemotherapy alone in paediatric
acute myeloid leukemia: results of the United Kingdom
Medical Research Council's 10th AML trial. MRC Childhood
Leukaemia Working Party.  Br J Haematol 1998, 101:130-40.
5. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J,
Berthold F, Henze G, Jurgens H, Kabisch H, Havers W, Reiter A,
Kluba U, Niggli F, Gadner H: Improved treatment results in
high-risk pediatric acute myeloid leukemia patients after
intensification with high-dose cytarabine and mitoxantrone:
results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-
Munster 93.  J Clin Oncol 2001, 19:2705-13.
6. Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B, Gan-
demer V, Schmitt C, Lamagnere JP, De Lumley L, Bader-Meunier B,
Couillaud G, Schaison G, Landman-Parker J, Thuret I, Dalle JH,
Baruchel A, Leverger G: Group LAME of the French Society of
Pediatric Hematology and Immunology. Impact of addition
of maintenance therapy to intensive induction and consoli-
dation chemotherapy for childhood acute myeloblastic
leukemia: results of a prospective randomized trial, LAME
89/91.  J Clin Oncol 2002, 20:2774-82.
7. Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ,
Kim K, Mosher DF, Wiersma SR, Longo WL: Fludarabine and
cytarabine as a sequential infusion regimen for treatment of
adults with recurrent, refractory or poor prognosis acute
leukemia.  Leuk Lymphoma 2001, 41:321-31.
8. Santana VM, Mirro J Jr, Harwood FC, Cherrie J, Schell M, Kalwinsky
D, Blakley RL: A phase I trial of 2-chlorodeoxyadenosine in
pediatric patients with acute leukemia.  J Clin Oncol 1991,
9:416-22.
9. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakley RL: 2-
Chlorodeoxyadenosine produces a high rate of complete
hematologic remission in relapsed acute myeloid leukemia.
J Clin Oncol 1992, 10:364-70.
10. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H,
Riehm H, Schellong G, Ludwig WD: Clinical significance of sur-
face antigen expression in children with acute myeloid leuke-
mia: results of study AML-BFM-87.  Blood 1995, 86:3097-108.
11. Andrews RG, Singer JW, Bernstein ID: Precursors of colony-
forming cells in humans can be distinguished from colony-
forming cells by expression of the CD33 and CD34 antigens
and light scatter properties.  J Exp Med 1989, 169:1721-31.
12. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D,
Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID: Selective
ablation of acute myeloid leukemia using antibody-targeted
chemotherapy: a phase I study of an anti-CD33 calicheam-
icin immunoconjugate.  Blood 1999, 93:3678-84.
13. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dom-
bret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS,
Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR,
Mylotarg Study Group: Efficacy and safety of gemtuzumab ozo-
gamicin in patients with CD33-positive acute myeloid leuke-
mia in first relapse.  J Clin Oncol 2001, 19:3244-54.
14. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R,
Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA,
Bernstein I: Gemtuzumab ozogamicin, a potent and selective
anti-CD33 antibody-calicheamicin conjugate for treatment
of acute myeloid leukemia.  Bioconjug Chem 2002, 13:47-58.
15. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upesla-
cis J: Preparation and characterization of monoclonal anti-
body conjugates of the calicheamicins: a novel and potent
family of antitumor antibiotics.  Cancer Res 1993, 53:3336-42.
16. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara
R, Rahman A, Williams G, Pazdur R: Approval summary: gemtu-
zumab ozogamicin in relapsed acute myeloid leukemia.  Clin
Cancer Res 2001, 7:1490-6.
17. Leopold LH, Berger MS, Feingold J: Acute and long-term toxici-
ties associated with gemtuzumab ozogamicin (mylotarg®)
therapy of acute myeloid leukemia.  Clin Lymphoma 2002,
2(suppl):S29-34.
18. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB: Hepatic sinu-
soidal obstruction after gemtuzumab ozogamicin (Mylo-
targ) therapy.  Blood 2002, 99:2310-4.
19. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G,
Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH:
Mylotarg (gemtuzumab ozogamicin) therapy is associated
with hepatic venoocclusive disease in patients who have not
received stem cell transplantation.  Cancer 2001, 92:406-13.
20. Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ,
Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA: Gemtuzumab ozo-
gamicin (Mylotarg) monotherapy for relapsed AML after
hematopoietic stem cell transplant: efficacy and incidence of
hepatic veno-occlusive disease.  Bone Marrow Transplant 2002,
30:23-28.
21. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Antin
EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzu-
mab ozogamicin exposure significantly increases the risk of
veno-occlusive disease in patients who undergo myeloabla-
tive allogeneic stem cell transplantation.  Blood 2003,
102:1578-82.
22. Sievers EL, Arceci R, Franklin J: Preliminary report of an ascend-
ing dose study of gemtuzumab ozogamicin (Mylotarg, CMA-
676) in pediatric patients with acute myeloid leukemia.  Blood
2000, 96:217b. (Abstr.)
23. Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink
JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, Kaspers GJ:
Gemtuzumab ozogamicin: first clinical experience in chil-
dren with relapsed/refractory acute myeloid leukemia
treated on compassionate-use basis.  Blood 2003, 101:3868-71.
24. Reinhardt D, Diekamp S, Fleischhack G, Corbacioglu C, Jurgens H,
Dworzak M, Kaspers G, Creutzig U, Zwaan CM: GemtuzumabPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:172 http://www.biomedcentral.com/1471-2407/6/172
Page 7 of 7
(page number not for citation purposes)
ozogamicin (Mylotarg) in children with refractory or
relapsed acute myeloid leukemia.  Onkologie 2004, 27:269-72.
25. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik
TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bern-
stein I, Sievers EL: Safety and efficacy of gemtuzumab ozo-
gamicin (Mylotarg(R)) in pediatric patients with advanced
CD33-positive acute myeloid leukemia.  Blood 2005,
106:1183-8.
26. McCarthy AJ, Pitcher LA, Hann IM, Oakhill A: FLAG (fludarabine,
high-dose cytarabine, and G-CSF) for refractory and high-
risk relapsed acute leukemia in children.  Med Pediatr Oncol
1999, 32:411-15.
27. Cancer Therapy Evaluation Program, Common Terminol-
ogy Criteria for Adverse Events, version 3.0 DCTC, National
Cancer Institute, National Institutes of Health, Department
of Health and Human services, March 31, 2003.  .
28. Fleischhack G, Hasan C, Graf N, Mann G, Bode U: IDA-FLAG (ida-
rubicine, fludarabine, cytarabine, G-CSF), an effective remis-
sion-induction therapy for poor-prognosis AML of childhood
prior to allogeneic or autologous bone marrow transplanta-
tion: experiences of a phase II trial.  Br J Haematol 1998,
102:647-645.
29. Webb DKH: Management of relapsed acute myeloid leukae-
mia.  Br J Haematol 1999, 106:851-9.
30. Larson RA, Sievers ER, Stadtmauer EA: A final analysis of the effi-
cacy ans safety of gemtuzumab ozogamicin in 277 patients
with acute myeloid leukemia in first relapse.  Blood 2002,
100:338a. (Abstr.)
31. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culli-
gan D, Hunter A, Prentice AG, Milligan DW: A feasibility study of
simultaneous administration of gemtuzumab ozogamicin
with intensive chemotherapy in induction and consolidation
in younger patients with acute myeloid leukemia.  Blood 2003,
102:4277-83.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/172/pre
pub